Peter Taylor

The Kennedy Institute of Rheumatology Division, Imperial College London, United Kingdom

Peter C Taylor

Academic positions:
- Professor in Experimental Rheumatology
- Head of the clinical trials group at the Kennedy Institute of Rheumatology Division, Imperial College, London
- Honorary consultant rheumatologist; Charing Cross Hospital.

All industry positions (in last five years):
None declared

Research interests:
The role of hypoxia and angiogenesis in inflammatory joint disease
assessing disease activity with novel imaging technology; new outcome measurements in clinical trials (use of high frequency ultrasound and power Doppler) relationship of synovial vascularity and structural damage to joints in rheumatoid arthritis.

Any other information:
Editorial Boards:
Current Opinions in Pharmacology, Drug Therapy Today, Expert Opinion on Investigational Drugs, Molecular Biotechnology

Local and National Committees:
Hammersmith Hospitals Trust Research Committee
Ethical Review Process committee for animal experimentation,
Kennedy Institute Division Imperial College Faculty of Medicine
Department of Health National Specialised Rheumatology Working Group
Royal Society of Medicine. Rheumatology Council Member July, 2004

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Rheumatology & Clinical Immunology > Methods, measurements & outcomes in rheumatic disease (since 15 November 2005)

Links

http://www1.imperial.ac.uk/medicine/about/divisions/kennedy/clinical/taylor/default.html

All recent recommendations

• 3.0
  Comparison of the Effect of Denosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial.
  Recommended by Peter Taylor with Sonya Abraham
  
• 3.0
  B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
  Recommended by Peter Taylor with Thomas Tull and Sonya Abraham
  
• 3.0
  Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?
  Recommended by Peter Taylor with Sonya Abraham
  
• 3.0
  Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
  Recommended by Peter Taylor with Sonya Abraham and Thomas Tull
  
• 6.5
  Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
  Recommended by Jon Tobias, Peter Taylor with Dr. Sonya Abraham, Rene Rizzoli
  
• 3.0
  The effect of anti-tumor necrosis factor alpha treatment on the antibody response to influenza vaccination.
  Recommended by Peter Taylor with Dr. Sonya Abraham
  
• 3.0
  Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.
  Recommended by Peter Taylor
  
• 3.0
  Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.
  Recommended by Peter Taylor
  
• 6.5
  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
  Recommended by Michael Ward, Peter Taylor, Joel Gelfand
  
• 6.4
  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
  Recommended by Peter Taylor, Paul Emery